Scholarlink

Background <p>Chronic insomnia affects approximately one-third of adults globally, imposing substantial health burdens with limited effective treatments. Transcranial alternating current stimulation (tACS) emerges as a non-invasive neuromodulatory approach, though its efficacy and safety profile require systematic evaluation.</p> Methods <p>We systematically searched PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials through July 2025 for randomized controlled trials (RCTs) evaluating tACS in adults with chronic insomnia. Primary outcomes included Pittsburgh Sleep Quality Index (PSQI) scores, sleep onset latency (SOL), total sleep time (TST), and subjective sleep efficiency. Secondary outcomes encompassed remission/response rates, daytime disturbances, mood symptoms, and adverse events. Data were pooled using random-effects models. Risk of bias and evidence certainty were assessed via Cochrane RoB 2.0 and GRADE.</p> Results <p>Four RCTs (<i>n</i> = 247) were included. tACS significantly reduced SOL at 2 weeks (MD = −56.90 min; 95% CI: −74.44 to −39.36) and 4 weeks (MD = −52.20 min; −67.03 to −37.37), improved PSQI (MD = −5.73; −8.35 to −3.10; <i>p</i> &lt; 0.0001), increased TST (MD = +85.29 min; 33.42 to 137.15; <i>p</i> = 0.0013), and reduced daytime disturbances (MD = −0.94; −1.13 to −0.76; <i>p</i> &lt; 0.0001). Response rates favored tACS (RR = 11.21; 3.20–39.23; <i>p</i> = 0.0002). Mood improvements were not sustained beyond 8 weeks. No significant adverse events emerged versus sham (RR = 1.06; 0.16–6.95). Heterogeneity ranged moderate-to-high (I<sup>2</sup> = 46.9–97.2%).</p> Conclusion <p>tACS demonstrates rapid efficacy (2–6 weeks) and safety for core insomnia symptoms. Sustained benefits require protocol optimization and long-term evaluation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transcranial alternating current stimulation for chronic insomnia: a meta-analytic evaluation of sleep restoration and safety in adults

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月19日

查看全文
  • Yehia Nabil,
  • Nourhan Hatem,
  • Menna M. Aboelkhier,
  • Anas Mansour,
  • Kholoud Elsamman,
  • Salma Allam,
  • Aya Samy,
  • Kiro Ehab,
  • Ahmed Noufal,
  • Ahmad Alkheder

摘要

Background

Chronic insomnia affects approximately one-third of adults globally, imposing substantial health burdens with limited effective treatments. Transcranial alternating current stimulation (tACS) emerges as a non-invasive neuromodulatory approach, though its efficacy and safety profile require systematic evaluation.

Methods

We systematically searched PubMed, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials through July 2025 for randomized controlled trials (RCTs) evaluating tACS in adults with chronic insomnia. Primary outcomes included Pittsburgh Sleep Quality Index (PSQI) scores, sleep onset latency (SOL), total sleep time (TST), and subjective sleep efficiency. Secondary outcomes encompassed remission/response rates, daytime disturbances, mood symptoms, and adverse events. Data were pooled using random-effects models. Risk of bias and evidence certainty were assessed via Cochrane RoB 2.0 and GRADE.

Results

Four RCTs (n = 247) were included. tACS significantly reduced SOL at 2 weeks (MD = −56.90 min; 95% CI: −74.44 to −39.36) and 4 weeks (MD = −52.20 min; −67.03 to −37.37), improved PSQI (MD = −5.73; −8.35 to −3.10; p < 0.0001), increased TST (MD = +85.29 min; 33.42 to 137.15; p = 0.0013), and reduced daytime disturbances (MD = −0.94; −1.13 to −0.76; p < 0.0001). Response rates favored tACS (RR = 11.21; 3.20–39.23; p = 0.0002). Mood improvements were not sustained beyond 8 weeks. No significant adverse events emerged versus sham (RR = 1.06; 0.16–6.95). Heterogeneity ranged moderate-to-high (I2 = 46.9–97.2%).

Conclusion

tACS demonstrates rapid efficacy (2–6 weeks) and safety for core insomnia symptoms. Sustained benefits require protocol optimization and long-term evaluation.